Eng-Mong Lim

Title: Eng-Mong Lim: Innovator in Tuberculosis Diagnostics and Treatment

Introduction

Eng-Mong Lim is a notable inventor based in Paris, France. He has made significant contributions to the field of biotechnology, particularly in the diagnosis and prevention of tuberculosis. His work focuses on the development of innovative solutions that leverage recombinant vectors and polypeptide nucleic sequences.

Latest Patents

Eng-Mong Lim holds a patent for "Polypeptide nucleic sequences exported from mycobacteria, vectors comprising same and uses for diagnosing and preventing tuberculosis." This invention involves recombinant vectors replicated in mycobacteria, which include a set of sequences coding for exported polypeptides. One notable polypeptide, called DP428, corresponds to an exported protein found in mycobacteria. The invention also encompasses methods and kits for detecting the presence of mycobacteria in biological samples, as well as immunogenic or vaccine compositions aimed at preventing and treating infections caused by these bacteria.

Career Highlights

Eng-Mong Lim is affiliated with the prestigious Institut Pasteur, where he continues to advance research in infectious diseases. His work has been instrumental in developing diagnostic tools and therapeutic strategies for tuberculosis, a disease that remains a significant global health challenge.

Collaborations

Eng-Mong Lim has collaborated with esteemed colleagues such as Brigitte Gicquel and Denis Portnoï. These partnerships have enhanced the impact of his research and contributed to the advancement of knowledge in the field of mycobacterial infections.

Conclusion

Eng-Mong Lim's innovative work in the realm of tuberculosis diagnostics and treatment exemplifies the critical role of inventors in addressing global health issues. His contributions continue to pave the way for advancements in biotechnology and infectious disease management.